AstraZeneca and Alteogen Inc. have entered into an exclusive license agreement for ALT-B4, a novel hyaluronidase utilising Hybrozyme™ platform technology. Under the terms of the agreement, AstraZeneca will acquire worldwide rights to use ALT-B4 to develop and commercialise subcutaneous formulations of several oncology assets. Alteogen will be responsible for clinical and commercial supply of ALT-B4 to AstraZeneca.

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it has entered into an exclusive collaboration and licensing agreement with Zealand Pharma (Nasdaq Copenhagen: ZEAL) (CVR-no. 20045078). Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialise petrelintide, Zealand Pharma's amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

Bayer and Hurdle have published groundbreaking research that represents a great advancement in aging research. The research introduces and validates a novel saliva-based DNA methylation biomarker designed to quantify systemic chronic inflammation (SCI), that the researchers have named, InflammAge. This innovative approach provides a non-invasive method for quantifying and tracking inflammation-related epigenetic biomarkers associated with aging.

GSK plc (LSE/NYSE: GSK) announced that it has completed the acquisition of IDRx, Inc. (IDRx), a Boston-based, clinical-stage biopharmaceutical company dedicated to developing precision therapeutics for the treatment of gastrointestinal stromal tumours (GIST).

As announced previously(1), the acquisition includes lead molecule IDRX-42, an investigational, highly selective tyrosine kinase inhibitor (TKI) that is designed to improve outcomes for patients with GIST.

Roche (SIX: RO, ROG; OTCQX: RHHBY), announced that the U.S. Food and Drug Administration (FDA) has approved a New Drug Application (NDA) for an Evrysdi® (risdiplam) tablet for people living with spinal muscular atrophy (SMA). Evrysdi is the only non-invasive disease-modifying treatment for SMA. The 5 mg Evrysdi tablet can either be swallowed whole or dispersed in water.

AskBio Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, today announced that investigational gene therapy AB-1005 for the treatment of Parkinson's disease (PD) has been granted Regenerative Medicine Advanced Therapy (RMAT) designation from the United States Food and Drug Administration (FDA).

As leaders gather for the World Economic Forum Annual Meeting 2025 in Davos, Leaps by Bayer, the impact investing arm of Bayer, and Boston Consulting Group (BCG) announced the launch of one of the largest surveys examining global public sentiment towards transformative technology. The field work was conducted by market research company Ipsos.